

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	All Sites	Henry Ford	Ohio State U	Cleveland Clinic Main	U of Washington	U of Vermont	U of Pittsburgh
Participants Enrolled	213	7	13	5	4	2	1
Participant's first dose administration compared to randomization							
Less than or equal to 4 hours after randomization	165 (77.5%)	7 (100.0%)	13 (100.0%)	5 (100.0%)	3 (75.0%)	1 (50.0%)	1 (100.0%)
More than 4 hours but less than or equal to 5 hours after randomization	20 (9.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
More than 5 hours after randomization	20 (9.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (25.0%)	1 (50.0%)	0 (0.0%)
Unreported time of first dose administration	8 (3.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Participants with reported first study product dose							
Participants with first dose less than or equal to 120 hours after hospital admission	205 (100.0%)	7 (100.0%)	13 (100.0%)	5 (100.0%)	4 (100.0%)	2 (100.0%)	1 (100.0%)
Participants with first dose more than 120 hours after hospital admission	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Participants with unreported time of hospital admission	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 1: Number of participant first doses expected							
Number of doses completed	226 (95.8%)	8 (80.0%)	13 (100.0%)	6 (100.0%)	5 (100.0%)	3 (100.0%)	2 (100.0%)
Number of doses missed	10 (4.2%)	2 (20.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 2: Number of doses expected							
Number of doses completed	332 (83.0%)	10 (71.4%)	22 (84.6%)	9 (90.0%)	7 (87.5%)	4 (100.0%)	2 (100.0%)
Number of doses missed	67 (16.8%)	4 (28.6%)	4 (15.4%)	1 (10.0%)	1 (12.5%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 3: Number of doses expected							
Number of doses completed	329 (85.9%)	11 (78.6%)	21 (87.5%)	10 (100.0%)	7 (87.5%)	4 (100.0%)	2 (100.0%)
Number of doses missed	54 (14.1%)	3 (21.4%)	3 (12.5%)	0 (0.0%)	1 (12.5%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 4: Number of doses expected							
Number of doses completed	310 (84.9%)	8 (66.7%)	21 (87.5%)	8 (88.9%)	7 (87.5%)	4 (100.0%)	2 (100.0%)
Number of doses missed	54 (14.8%)	4 (33.3%)	3 (12.5%)	1 (11.1%)	1 (12.5%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	1 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	Washington U St Louis	Wake Forest	Johns Hopkins Hosp.	U of Cincinnati	Medical U South Carolina	Intermountai n	Vanderbilt U
Participants Enrolled	9	8	32	25	7	22	8
Participant's first dose administration compared to randomization							
Less than or equal to 4 hours after randomization	1 (11.1%)	8 (100.0%)	22 (68.8%)	17 (68.0%)	6 (85.7%)	17 (77.3%)	7 (87.5%)
More than 4 hours but less than or equal to 5 hours after randomization	2 (22.2%)	0 (0.0%)	3 (9.4%)	6 (24.0%)	1 (14.3%)	1 (4.5%)	0 (0.0%)
More than 5 hours after randomization	5 (55.6%)	0 (0.0%)	5 (15.6%)	2 (8.0%)	0 (0.0%)	2 (9.1%)	0 (0.0%)
Unreported time of first dose administration	1 (11.1%)	0 (0.0%)	2 (6.3%)	0 (0.0%)	0 (0.0%)	2 (9.1%)	1 (12.5%)
Participants with reported first study product dose	8	8	30	25	7	20	7
Participants with first dose less than or equal to 120 hours after hospital admission	8 (100.0%)	8 (100.0%)	30 (100.0%)	25 (100.0%)	7 (100.0%)	20 (100.0%)	7 (100.0%)
Participants with first dose more than 120 hours after hospital admission	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Participants with unreported time of hospital admission	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 1: Number of participant first doses expected	8	8	38	26	7	20	7
Number of doses completed	8 (100.0%)	8 (100.0%)	34 (89.5%)	25 (96.2%)	7 (100.0%)	20 (100.0%)	7 (100.0%)
Number of doses missed	0 (0.0%)	0 (0.0%)	4 (10.5%)	1 (3.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 2: Number of doses expected	16	14	58	48	14	39	14
Number of doses completed	13 (81.3%)	13 (92.9%)	42 (72.4%)	43 (89.6%)	13 (92.9%)	33 (84.6%)	10 (71.4%)
Number of doses missed	3 (18.8%)	1 (7.1%)	16 (27.6%)	5 (10.4%)	1 (7.1%)	6 (15.4%)	4 (28.6%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 3: Number of doses expected	14	13	56	47	14	38	12
Number of doses completed	11 (78.6%)	13 (100.0%)	43 (76.8%)	42 (89.4%)	12 (85.7%)	34 (89.5%)	9 (75.0%)
Number of doses missed	3 (21.4%)	0 (0.0%)	13 (23.2%)	5 (10.6%)	2 (14.3%)	4 (10.5%)	3 (25.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 4: Number of doses expected	14	12	54	42	14	37	11
Number of doses completed	12 (85.7%)	12 (100.0%)	40 (74.1%)	38 (90.5%)	12 (85.7%)	31 (83.8%)	9 (81.8%)
Number of doses missed	2 (14.3%)	0 (0.0%)	14 (25.9%)	4 (9.5%)	2 (14.3%)	6 (16.2%)	2 (18.2%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	Montefiore Moses	U of Michigan	U of Colorado Denver	U of Wash. Harborview	Johns Hopkins Bayview	Montefiore Weiler
Participants Enrolled	6	1	20	9	33	1
Participant's first dose administration compared to randomization						
Less than or equal to 4 hours after randomization	5 (83.3%)	0 (0.0%)	17 (85.0%)	7 (77.8%)	27 (81.8%)	1 (100.0%)
More than 4 hours but less than or equal to 5 hours after randomization	0 (0.0%)	0 (0.0%)	1 (5.0%)	2 (22.2%)	4 (12.1%)	0 (0.0%)
More than 5 hours after randomization	0 (0.0%)	1 (100.0%)	1 (5.0%)	0 (0.0%)	2 (6.1%)	0 (0.0%)
Unreported time of first dose administration	1 (16.7%)	0 (0.0%)	1 (5.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Participants with reported first study product dose						
Participants with first dose less than or equal to 120 hours after hospital admission	5 (100.0%)	1 (100.0%)	19 (100.0%)	9 (100.0%)	33 (100.0%)	1 (100.0%)
Participants with first dose more than 120 hours after hospital admission	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Participants with unreported time of hospital admission	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 1: Number of participant first doses expected						
Number of doses completed	4 (80.0%)	1 (100.0%)	21 (100.0%)	11 (100.0%)	42 (95.5%)	1 (100.0%)
Number of doses missed	1 (20.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.5%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 2: Number of doses expected						
Number of doses completed	8 (80.0%)	1 (50.0%)	32 (88.9%)	18 (100.0%)	51 (78.5%)	1 (50.0%)
Number of doses missed	2 (20.0%)	1 (50.0%)	4 (11.1%)	0 (0.0%)	13 (20.0%)	1 (50.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.5%)	0 (0.0%)
Day 3: Number of doses expected						
Number of doses completed	8 (80.0%)	1 (50.0%)	31 (91.2%)	16 (100.0%)	53 (84.1%)	1 (50.0%)
Number of doses missed	2 (20.0%)	1 (50.0%)	3 (8.8%)	0 (0.0%)	10 (15.9%)	1 (50.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 4: Number of doses expected						
Number of doses completed	9 (90.0%)	1 (50.0%)	28 (87.5%)	15 (100.0%)	51 (83.6%)	2 (100.0%)
Number of doses missed	1 (10.0%)	1 (50.0%)	4 (12.5%)	0 (0.0%)	9 (14.8%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)	0 (0.0%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	All Sites	Henry Ford	Ohio State U	Cleveland Clinic Main	U of Washington	U of Vermont	U of Pittsburgh
Day 5: Number of doses expected	340	9	22	8	8	4	2
Number of doses completed	291 (85.6%)	6 (66.7%)	20 (90.9%)	6 (75.0%)	6 (75.0%)	4 (100.0%)	2 (100.0%)
Number of doses missed	47 (13.8%)	3 (33.3%)	2 (9.1%)	2 (25.0%)	2 (25.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	2 (0.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 6: Number of doses expected	288	5	19	7	7	3	1
Number of doses completed	167 (58.0%)	4 (80.0%)	10 (52.6%)	6 (85.7%)	4 (57.1%)	1 (33.3%)	1 (100.0%)
Number of doses missed	111 (38.5%)	1 (20.0%)	9 (47.4%)	1 (14.3%)	3 (42.9%)	2 (66.7%)	0 (0.0%)
Number of doses unreported	10 (3.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 7: Number of doses expected	151	4	9	4	4	2	1
Number of doses completed	147 (97.4%)	4 (100.0%)	9 (100.0%)	3 (75.0%)	4 (100.0%)	2 (100.0%)	1 (100.0%)
Number of doses missed	4 (2.6%)	0 (0.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 8: Number of doses expected	137	4	7	3	4	1	1
Number of doses completed	128 (93.4%)	3 (75.0%)	7 (100.0%)	3 (100.0%)	3 (75.0%)	1 (100.0%)	1 (100.0%)
Number of doses missed	9 (6.6%)	1 (25.0%)	0 (0.0%)	0 (0.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 9: Number of doses expected	125	4	6	1	4	1	1
Number of doses completed	117 (93.6%)	3 (75.0%)	6 (100.0%)	0 (0.0%)	3 (75.0%)	1 (100.0%)	1 (100.0%)
Number of doses missed	8 (6.4%)	1 (25.0%)	0 (0.0%)	1 (100.0%)	1 (25.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 10: Number of doses expected	118	4	6	1	4	1	1
Number of doses completed	113 (95.8%)	4 (100.0%)	6 (100.0%)	0 (0.0%)	4 (100.0%)	1 (100.0%)	1 (100.0%)
Number of doses missed	5 (4.2%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 11: Number of doses expected	110	3	6	1	3	1	1
Number of doses completed	104 (94.5%)	2 (66.7%)	6 (100.0%)	0 (0.0%)	3 (100.0%)	1 (100.0%)	1 (100.0%)
Number of doses missed	6 (5.5%)	1 (33.3%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	Washington U St Louis	Wake Forest	Johns Hopkins Hosp.	U of Cincinnati	Medical U South Carolina	Intermountai n	Vanderbilt U
Day 5: Number of doses expected	11	11	49	40	14	35	10
Number of doses completed	10 (90.9%)	11 (100.0%)	40 (81.6%)	39 (97.5%)	11 (78.6%)	29 (82.9%)	8 (80.0%)
Number of doses missed	1 (9.1%)	0 (0.0%)	9 (18.4%)	1 (2.5%)	2 (14.3%)	6 (17.1%)	2 (20.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (7.1%)	0 (0.0%)	0 (0.0%)
Day 6: Number of doses expected	10	8	38	37	13	32	10
Number of doses completed	4 (40.0%)	6 (75.0%)	21 (55.3%)	21 (56.8%)	7 (53.8%)	20 (62.5%)	5 (50.0%)
Number of doses missed	6 (60.0%)	2 (25.0%)	17 (44.7%)	15 (40.5%)	5 (38.5%)	12 (37.5%)	5 (50.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.7%)	1 (7.7%)	0 (0.0%)	0 (0.0%)
Day 7: Number of doses expected	5	2	23	18	6	14	5
Number of doses completed	4 (80.0%)	2 (100.0%)	22 (95.7%)	18 (100.0%)	6 (100.0%)	13 (92.9%)	5 (100.0%)
Number of doses missed	1 (20.0%)	0 (0.0%)	1 (4.3%)	0 (0.0%)	0 (0.0%)	1 (7.1%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 8: Number of doses expected	4	2	22	18	5	11	5
Number of doses completed	4 (100.0%)	2 (100.0%)	20 (90.9%)	18 (100.0%)	5 (100.0%)	9 (81.8%)	5 (100.0%)
Number of doses missed	0 (0.0%)	0 (0.0%)	2 (9.1%)	0 (0.0%)	0 (0.0%)	2 (18.2%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 9: Number of doses expected	3	2	19	18	4	9	4
Number of doses completed	3 (100.0%)	2 (100.0%)	17 (89.5%)	17 (94.4%)	4 (100.0%)	8 (88.9%)	3 (75.0%)
Number of doses missed	0 (0.0%)	0 (0.0%)	2 (10.5%)	1 (5.6%)	0 (0.0%)	1 (11.1%)	1 (25.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 10: Number of doses expected	2	2	18	18	3	7	4
Number of doses completed	2 (100.0%)	2 (100.0%)	17 (94.4%)	18 (100.0%)	3 (100.0%)	7 (100.0%)	4 (100.0%)
Number of doses missed	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 11: Number of doses expected	1	2	18	18	2	6	4
Number of doses completed	1 (100.0%)	2 (100.0%)	17 (94.4%)	18 (100.0%)	2 (100.0%)	6 (100.0%)	4 (100.0%)
Number of doses missed	0 (0.0%)	0 (0.0%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	Montefiore Moses	U of Michigan	U of Colorado Denver	U of Wash. Harborview	Johns Hopkins Bayview	Montefiore Weiler
Day 5: Number of doses expected	10	2	32	14	58	1
Number of doses completed	10 (100.0%)	0 (0.0%)	29 (90.6%)	14 (100.0%)	45 (77.6%)	1 (100.0%)
Number of doses missed	0 (0.0%)	2 (100.0%)	3 (9.4%)	0 (0.0%)	12 (20.7%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.7%)	0 (0.0%)
Day 6: Number of doses expected	10	2	27	12	47	0
Number of doses completed	6 (60.0%)	1 (50.0%)	15 (55.6%)	6 (50.0%)	29 (61.7%)	0 (-%)
Number of doses missed	3 (30.0%)	1 (50.0%)	10 (37.0%)	3 (25.0%)	16 (34.0%)	0 (-%)
Number of doses unreported	1 (10.0%)	0 (0.0%)	2 (7.4%)	3 (25.0%)	2 (4.3%)	0 (-%)
Day 7: Number of doses expected	5	1	13	7	28	0
Number of doses completed	5 (100.0%)	1 (100.0%)	13 (100.0%)	7 (100.0%)	28 (100.0%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 8: Number of doses expected	4	1	12	7	26	0
Number of doses completed	4 (100.0%)	1 (100.0%)	11 (91.7%)	7 (100.0%)	24 (92.3%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (0.0%)	1 (8.3%)	0 (0.0%)	2 (7.7%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 9: Number of doses expected	4	1	12	7	25	0
Number of doses completed	4 (100.0%)	1 (100.0%)	12 (100.0%)	7 (100.0%)	25 (100.0%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 10: Number of doses expected	4	1	12	7	23	0
Number of doses completed	4 (100.0%)	1 (100.0%)	11 (91.7%)	7 (100.0%)	21 (91.3%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (0.0%)	1 (8.3%)	0 (0.0%)	2 (8.7%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 11: Number of doses expected	3	1	12	6	22	0
Number of doses completed	3 (100.0%)	1 (100.0%)	11 (91.7%)	6 (100.0%)	20 (90.9%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (0.0%)	1 (8.3%)	0 (0.0%)	2 (9.1%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	All Sites	Henry Ford	Ohio State U	Cleveland Clinic Main	U of Washington	U of Vermont	U of Pittsburgh
Day 12: Number of doses expected	102	3	4	1	3	1	1
Number of doses completed	97 (95.1%)	2 (66.7%)	4 (100.0%)	0 (0.0%)	3 (100.0%)	1 (100.0%)	1 (100.0%)
Number of doses missed	5 (4.9%)	1 (33.3%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 13: Number of doses expected	94	3	4	1	3	1	1
Number of doses completed	91 (96.8%)	3 (100.0%)	4 (100.0%)	1 (100.0%)	3 (100.0%)	1 (100.0%)	1 (100.0%)
Number of doses missed	3 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 14: Number of doses expected	88	2	3	1	3	0	1
Number of doses completed	84 (95.5%)	2 (100.0%)	3 (100.0%)	0 (0.0%)	3 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	4 (4.5%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 15: Number of doses expected	82	2	3	1	3	0	1
Number of doses completed	80 (97.6%)	2 (100.0%)	3 (100.0%)	1 (100.0%)	3 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	2 (2.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 16: Number of doses expected	74	1	3	1	3	0	1
Number of doses completed	69 (93.2%)	1 (100.0%)	3 (100.0%)	0 (0.0%)	3 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	5 (6.8%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 17: Number of doses expected	69	0	3	1	2	0	1
Number of doses completed	62 (89.9%)	0 (-%)	3 (100.0%)	0 (0.0%)	2 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	7 (10.1%)	0 (-%)	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 18: Number of doses expected	66	0	2	1	2	0	1
Number of doses completed	63 (95.5%)	0 (-%)	2 (100.0%)	1 (100.0%)	2 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	3 (4.5%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	Washington U St Louis	Wake Forest	Johns Hopkins Hosp.	U of Cincinnati	Medical U South Carolina	Intermountai n	Vanderbilt U
Day 12: Number of doses expected	1	0	18	17	2	6	4
Number of doses completed	1 (100.0%)	0 (-%)	17 (94.4%)	17 (100.0%)	2 (100.0%)	5 (83.3%)	4 (100.0%)
Number of doses missed	0 (0.0%)	0 (-%)	1 (5.6%)	0 (0.0%)	0 (0.0%)	1 (16.7%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 13: Number of doses expected	1	0	17	15	2	5	3
Number of doses completed	1 (100.0%)	0 (-%)	17 (100.0%)	15 (100.0%)	2 (100.0%)	4 (80.0%)	3 (100.0%)
Number of doses missed	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 14: Number of doses expected	1	0	16	14	2	4	3
Number of doses completed	1 (100.0%)	0 (-%)	16 (100.0%)	14 (100.0%)	2 (100.0%)	4 (100.0%)	3 (100.0%)
Number of doses missed	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 15: Number of doses expected	1	0	13	13	2	4	3
Number of doses completed	1 (100.0%)	0 (-%)	12 (92.3%)	13 (100.0%)	2 (100.0%)	4 (100.0%)	3 (100.0%)
Number of doses missed	0 (0.0%)	0 (-%)	1 (7.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 16: Number of doses expected	0	0	12	12	2	3	3
Number of doses completed	0 (-%)	0 (-%)	11 (91.7%)	11 (91.7%)	2 (100.0%)	3 (100.0%)	3 (100.0%)
Number of doses missed	0 (-%)	0 (-%)	1 (8.3%)	1 (8.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 17: Number of doses expected	0	0	12	12	2	2	2
Number of doses completed	0 (-%)	0 (-%)	11 (91.7%)	12 (100.0%)	1 (50.0%)	1 (50.0%)	2 (100.0%)
Number of doses missed	0 (-%)	0 (-%)	1 (8.3%)	0 (0.0%)	1 (50.0%)	1 (50.0%)	0 (0.0%)
Number of doses unreported	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 18: Number of doses expected	0	0	12	12	2	2	2
Number of doses completed	0 (-%)	0 (-%)	12 (100.0%)	12 (100.0%)	2 (100.0%)	2 (100.0%)	2 (100.0%)
Number of doses missed	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	Montefiore Moses	U of Michigan	U of Colorado Denver	U of Wash. Harborview	Johns Hopkins Bayview	Montefiore Weiler
Day 12: Number of doses expected	2	1	11	6	21	0
Number of doses completed	2 (100.0%)	1 (100.0%)	10 (90.9%)	6 (100.0%)	21 (100.0%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (0.0%)	1 (9.1%)	0 (0.0%)	0 (0.0%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 13: Number of doses expected	1	1	11	5	20	0
Number of doses completed	1 (100.0%)	1 (100.0%)	10 (90.9%)	5 (100.0%)	19 (95.0%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (0.0%)	1 (9.1%)	0 (0.0%)	1 (5.0%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 14: Number of doses expected	1	1	11	5	20	0
Number of doses completed	1 (100.0%)	1 (100.0%)	10 (90.9%)	5 (100.0%)	18 (90.0%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (0.0%)	1 (9.1%)	0 (0.0%)	2 (10.0%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 15: Number of doses expected	1	1	11	5	18	0
Number of doses completed	1 (100.0%)	1 (100.0%)	10 (90.9%)	5 (100.0%)	18 (100.0%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (0.0%)	1 (9.1%)	0 (0.0%)	0 (0.0%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 16: Number of doses expected	1	1	10	5	16	0
Number of doses completed	1 (100.0%)	1 (100.0%)	9 (90.0%)	5 (100.0%)	15 (93.8%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (0.0%)	1 (10.0%)	0 (0.0%)	1 (6.3%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 17: Number of doses expected	1	1	9	5	16	0
Number of doses completed	1 (100.0%)	0 (0.0%)	9 (100.0%)	5 (100.0%)	14 (87.5%)	0 (-%)
Number of doses missed	0 (0.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	2 (12.5%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 18: Number of doses expected	1	0	8	5	16	0
Number of doses completed	1 (100.0%)	0 (-%)	7 (87.5%)	5 (100.0%)	14 (87.5%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (-%)	1 (12.5%)	0 (0.0%)	2 (12.5%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	All Sites	Henry Ford	Ohio State U	Cleveland Clinic Main	U of Washington	U of Vermont	U of Pittsburgh
Day 19: Number of doses expected	60	0	2	0	2	0	1
Number of doses completed	56 (93.3%)	0 (-%)	2 (100.0%)	0 (-%)	2 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	4 (6.7%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 20: Number of doses expected	58	0	2	0	2	0	1
Number of doses completed	55 (94.8%)	0 (-%)	2 (100.0%)	0 (-%)	2 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	3 (5.2%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 21: Number of doses expected	53	0	2	0	2	0	1
Number of doses completed	48 (90.6%)	0 (-%)	2 (100.0%)	0 (-%)	2 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	5 (9.4%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 22: Number of doses expected	51	0	2	0	2	0	1
Number of doses completed	47 (92.2%)	0 (-%)	2 (100.0%)	0 (-%)	2 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	4 (7.8%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 23: Number of doses expected	46	0	1	0	2	0	1
Number of doses completed	39 (84.8%)	0 (-%)	1 (100.0%)	0 (-%)	2 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	7 (15.2%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 24: Number of doses expected	42	0	1	0	1	0	1
Number of doses completed	37 (88.1%)	0 (-%)	1 (100.0%)	0 (-%)	1 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	5 (11.9%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 25: Number of doses expected	40	0	0	0	1	0	1
Number of doses completed	38 (95.0%)	0 (-%)	0 (-%)	0 (-%)	1 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	2 (5.0%)	0 (-%)	0 (-%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (-%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	Washington U St Louis	Wake Forest	Johns Hopkins Hosp.	U of Cincinnati	Medical U South Carolina	Intermountai n	Vanderbilt U
Day 19: Number of doses expected	0	0	12	9	2	1	2
Number of doses completed	0 (-%)	0 (-%)	10 (83.3%)	9 (100.0%)	1 (50.0%)	1 (100.0%)	2 (100.0%)
Number of doses missed	0 (-%)	0 (-%)	2 (16.7%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 20: Number of doses expected	0	0	12	9	2	1	2
Number of doses completed	0 (-%)	0 (-%)	11 (91.7%)	9 (100.0%)	2 (100.0%)	1 (100.0%)	2 (100.0%)
Number of doses missed	0 (-%)	0 (-%)	1 (8.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of doses unreported	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Day 21: Number of doses expected	0	0	12	9	2	0	2
Number of doses completed	0 (-%)	0 (-%)	10 (83.3%)	9 (100.0%)	1 (50.0%)	0 (-%)	2 (100.0%)
Number of doses missed	0 (-%)	0 (-%)	2 (16.7%)	0 (0.0%)	1 (50.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 22: Number of doses expected	0	0	12	7	2	0	2
Number of doses completed	0 (-%)	0 (-%)	9 (75.0%)	7 (100.0%)	2 (100.0%)	0 (-%)	2 (100.0%)
Number of doses missed	0 (-%)	0 (-%)	3 (25.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 23: Number of doses expected	0	0	11	5	2	0	2
Number of doses completed	0 (-%)	0 (-%)	9 (81.8%)	5 (100.0%)	1 (50.0%)	0 (-%)	2 (100.0%)
Number of doses missed	0 (-%)	0 (-%)	2 (18.2%)	0 (0.0%)	1 (50.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 24: Number of doses expected	0	0	10	5	2	0	1
Number of doses completed	0 (-%)	0 (-%)	8 (80.0%)	5 (100.0%)	2 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	0 (-%)	0 (-%)	2 (20.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 25: Number of doses expected	0	0	10	5	2	0	1
Number of doses completed	0 (-%)	0 (-%)	8 (80.0%)	5 (100.0%)	2 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	0 (-%)	0 (-%)	2 (20.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	Montefiore Moses	U of Michigan	U of Colorado Denver	U of Wash. Harborview	Johns Hopkins Bayview	Montefiore Weiler
Day 19: Number of doses expected	1	0	8	5	15	0
Number of doses completed	1 (100.0%)	0 (-%)	7 (87.5%)	5 (100.0%)	15 (100.0%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (-%)	1 (12.5%)	0 (0.0%)	0 (0.0%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 20: Number of doses expected	1	0	7	5	14	0
Number of doses completed	1 (100.0%)	0 (-%)	7 (100.0%)	5 (100.0%)	12 (85.7%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	2 (14.3%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 21: Number of doses expected	1	0	5	4	13	0
Number of doses completed	1 (100.0%)	0 (-%)	4 (80.0%)	4 (100.0%)	12 (92.3%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (-%)	1 (20.0%)	0 (0.0%)	1 (7.7%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 22: Number of doses expected	1	0	5	4	13	0
Number of doses completed	1 (100.0%)	0 (-%)	5 (100.0%)	4 (100.0%)	12 (92.3%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 23: Number of doses expected	1	0	5	4	12	0
Number of doses completed	1 (100.0%)	0 (-%)	4 (80.0%)	3 (75.0%)	10 (83.3%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (-%)	1 (20.0%)	1 (25.0%)	2 (16.7%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 24: Number of doses expected	1	0	5	4	11	0
Number of doses completed	1 (100.0%)	0 (-%)	4 (80.0%)	4 (100.0%)	9 (81.8%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (-%)	1 (20.0%)	0 (0.0%)	2 (18.2%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 25: Number of doses expected	1	0	5	4	10	0
Number of doses completed	1 (100.0%)	0 (-%)	5 (100.0%)	4 (100.0%)	10 (100.0%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	All Sites	Henry Ford	Ohio State U	Cleveland Clinic Main	U of Washington	U of Vermont	U of Pittsburgh
Day 26: Number of doses expected	36	0	0	0	1	0	1
Number of doses completed	32 (88.9%)	0 (-%)	0 (-%)	0 (-%)	1 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	4 (11.1%)	0 (-%)	0 (-%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (-%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 27: Number of doses expected	33	0	0	0	1	0	1
Number of doses completed	32 (97.0%)	0 (-%)	0 (-%)	0 (-%)	1 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	1 (3.0%)	0 (-%)	0 (-%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (-%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 28: Number of doses expected	28	0	0	0	1	0	1
Number of doses completed	28 (100.0%)	0 (-%)	0 (-%)	0 (-%)	1 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	0 (0.0%)	0 (-%)	0 (-%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (-%)	0 (-%)	0 (0.0%)	0 (-%)	0 (0.0%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	Washington U St Louis	Wake Forest	Johns Hopkins Hosp.	U of Cincinnati	Medical U South Carolina	Intermountai n	Vanderbilt U
Day 26: Number of doses expected	0	0	10	3	2	0	1
Number of doses completed	0 (-%)	0 (-%)	8 (80.0%)	3 (100.0%)	2 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	0 (-%)	0 (-%)	2 (20.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 27: Number of doses expected	0	0	9	3	2	0	1
Number of doses completed	0 (-%)	0 (-%)	8 (88.9%)	3 (100.0%)	2 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	0 (-%)	0 (-%)	1 (11.1%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Day 28: Number of doses expected	0	0	8	2	2	0	1
Number of doses completed	0 (-%)	0 (-%)	8 (100.0%)	2 (100.0%)	2 (100.0%)	0 (-%)	1 (100.0%)
Number of doses missed	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)
Number of doses unreported	0 (-%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)	0 (0.0%)

**GRAIL3 – Ganciclovir to Prevent Reactivation of CMV in Patients with Acute Respiratory Failure and Sepsis
Atlas Open Report – Data as of May 23, 2026**

Table O3 – Study Product Administration by Site

	Montefiore Moses	U of Michigan	U of Colorado Denver	U of Wash. Harborview	Johns Hopkins Bayview	Montefiore Weiler
Day 26: Number of doses expected	1	0	4	4	9	0
Number of doses completed	1 (100.0%)	0 (-%)	3 (75.0%)	4 (100.0%)	8 (88.9%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (-%)	1 (25.0%)	0 (0.0%)	1 (11.1%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 27: Number of doses expected	1	0	2	4	9	0
Number of doses completed	1 (100.0%)	0 (-%)	2 (100.0%)	4 (100.0%)	9 (100.0%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Day 28: Number of doses expected	1	0	1	4	7	0
Number of doses completed	1 (100.0%)	0 (-%)	1 (100.0%)	4 (100.0%)	7 (100.0%)	0 (-%)
Number of doses missed	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)
Number of doses unreported	0 (0.0%)	0 (-%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (-%)